Avenue Therapeutics, Inc. (ATXI) Revenue History
Annual and quarterly revenue from 2015 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ATXI Revenue Growth
ATXI Revenue Analysis (2015–2024)
As of May 8, 2026, Avenue Therapeutics, Inc. (ATXI) generated trailing twelve-month (TTM) revenue of $1.4 million. The most recent quarter (Q3 2025) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, ATXI's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including PCRX (+4.6% YoY), COLL (+19.9% YoY), and MNKD (+21.2% YoY). Compare ATXI vs PCRX →
ATXI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ATXICurrent | $1M | - | - | - | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 COLL | $781M | +19.9% | +20.3% | 24.0% | |
 MNKD | $349M | +21.2% | +39.9% | 11.1% | |
 XTLB | $451,000 | - | - | -481.6% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% |
ATXI Historical Revenue Data (2015–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $0 | - | $-11,283,000 | - |
| 2023 | $0 | - | $0 | - | $-14,540,000 | - |
| 2022 | $0 | - | $0 | - | $-8,043,000 | - |
| 2021 | $0 | - | $0 | - | $-3,738,000 | - |
| 2020 | $0 | - | $0 | - | $-5,213,000 | - |
| 2019 | $0 | - | $0 | - | $-26,265,000 | - |
| 2018 | $0 | - | $0 | - | $-21,816,000 | - |
| 2017 | $0 | - | $0 | - | $-11,421,000 | - |
| 2016 | $0 | - | $0 | - | $-2,377,000 | - |
| 2015 | $0 | - | $0 | - | $-4,843,000 | - |
See ATXI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ATXI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ATXI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonATXI — Frequently Asked Questions
Quick answers to the most common questions about buying ATXI stock.
Is ATXI's revenue growth accelerating or slowing?
ATXI TTM revenue: $1M. YoY growth: N/A. 5-year CAGR: N/A.
What is ATXI's long-term revenue growth rate?
Avenue Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is ATXI's revenue distributed by segment?
ATXI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2024 are available for download. Segment mix reveals concentration and diversification trends.